IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

ACORDA THERAPEUTICS, INC. and ALKERMES PHARMA IRELAND LIMITED,)	
Plaintiffs,)	
V.)	C.A. No. 14-917 (LPS
ALKEM LABORATORIES LTD. and ASCEND LABORATORIES, LLC.)	
Defendants.)	
	}	

CONSENT JUDGMENT

WHEREAS, this action for patent infringement has been brought by Plaintiffs Acorda Therapeutics, Inc. and Alkermes Pharma Ireland Limited (collectively, "Acorda") against Defendants Alkem Laboratories Ltd. and Ascend Laboratories, LLC (collectively, "Alkem") for infringement of United States Patent Nos. 5,540,938, 8,077,826, 8,354,437, 8,440,703, and 8,663,685 (the "Patents" and such action, the "Litigation"); and

WHEREAS, the parties in the Litigation have entered into a good faith final settlement agreement dated on or about June 29, 2016 to fully settle the Litigation (the "Settlement Agreement");

The Court, upon the consent and request of the parties in the Litigation, hereby acknowledges the following Consent Judgment and, upon due consideration, issues the following Order.

IT IS HEREBY ORDERED, ADJUDGED AND DECREED that:

- Subject matter jurisdiction, personal jurisdiction, and venue are all proper in this
 Court.
 - 2. The Patents are enforceable and valid.

- 3. Alkem has infringed the Patents pursuant to 35 U.S.C. §271(e)(2) by filing Abbreviated New Drug Application No. 206765.
- 4. Except as and to the extent permitted by the Settlement Agreement, Alkem and its Affiliates, including any of its successors and assigns, is enjoined from making, having made, using, selling, offering to sell, importing or distributing any dalfampridine product pursuant to Abbreviated New Drug Application 206765, either directly or indirectly, on its own part or through any Affiliate, officer, agent, servant, employee or attorney, or through any person in concert or coordination with Alkem or any of its Affiliates, until the license to the Patents provided in the Settlement Agreement becomes effective as set forth in the Settlement Agreement.
- 5. For purposes of this Consent Judgment, the term "Affiliate" shall have the meaning set forth in the Settlement Agreement.
- 6. Except to the extent set forth above and in the Settlement Agreement all claims and counterclaims, affirmative defenses and demands of the Parties in this action are hereby dismissed with prejudice and without costs, disbursements, or attorneys' fees, to any Party.
- 7. The Parties each expressly waive any right to appeal or otherwise move for relief from this Consent Judgment.
- 8. Compliance with this Consent Judgment may be enforced by the Parties and their successors in interest, or assigns, as permitted by the terms of the Settlement Agreement.
- 9. This Court retains jurisdiction over the Parties for purposes of enforcing this Consent Judgment as well as any dispute regarding the Settlement Agreement.
- 10. The Clerk of the Court is directed to enter this Consent Judgment and Order forthwith.

MORRIS, NICHOLS. ARSHT & TUNNELL LLP

PHILLIPS, GOLDMAN, McLaughlin & Hall

/s/Jeremy A. Tigan

Jack B. Blumenfeld (#1014)
Maryellen Noreika (#3208)
Jeremy A. Tigan (#5239)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899-1347
(302) 658-9200
jblumenfeld@mnat.com
mnoreika@mnat.com
jtigan@mnat.com

OF COUNSEL:

Aaron Stiefel Daniel P. DiNapoli KAYE SCHOLER LLP 425 Park Avenue New York, NY 10022-3598

Sylvia M. Becker KAYE SCHOLER LLP 901 Fifteenth Street, N.W. Washington, DC 20005-2327

Counsel for Acorda Therapeutics, Inc. and Alkermes Pharma Ireland Limited

SO ORDERED this \(\frac{1}{2} \) day of

August 4, 2016

/s/ Megan C. Haney

John C. Phillips, Jr. (#110) Megan C. Haney (#5016) 1200 North Broom Street Wilmington, DE 19806 (302) 655-4200 jcp@pgmhlaw.com mch@pgmhlaw.com

OF COUNSEL:

Imron T. Aly Nimita L. Parekh SCHIFF HARDIN LLP 233 South Wacker Drive, Suite 6600 Chicago, IL 60606

Counsel for Alkem Laboratories Ltd. and Ascend Laboratories, LLC

CHIEF. UNITED STATES DISTRICT JUDGE